查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1736518

2026 年至 2032 年成人疫苗市場（按疫苗、疫苗類型、技術、最終用戶和地區分類）

Adult Vaccine Market By Vaccine, Vaccine Type, Technology, End-User, & Region for 2026-2032
出版日期: | 出版商: Verified Market Research | 英文 | 商品交期: 2-3個工作天內

價格
簡介目錄

成人疫苗市場評估 - 2026-2032

流感、肝炎和帶狀皰疹等感染疾病的流行，以及政府為提高人們對疫苗重要性的認知而推出的項目，正在推動成人疫苗市場的擴張。本研究報告對全球成人疫苗市場進行了全面評估。預計2024年市場規模將超過172.7987億美元，2032年將達到約277.5004億美元。

此外，疫苗接種技術研究的不斷增加和政府資金的增加使得市場在 2026-2032 年期間的複合年成長率達到 6.10%。

成人疫苗市場定義/概述

成人疫苗是專為18歲及以上人群設計的疫苗，用於預防感染疾病，並降低重症、併發症和病原體傳播的風險。這些疫苗作為基礎疫苗或加強疫苗接種，以維持兒童疫苗誘發的免疫力。

常見的成人疫苗包括流感疫苗、破傷風疫苗、白喉疫苗、百日咳疫苗、肺炎疫苗、帶狀皰疹疫苗、人類乳突病毒疫苗 (HPV)、甲型肝炎疫苗、B型肝炎疫苗、麻疹疫苗、腮腺炎疫苗、德國德國麻疹(MMR)、水痘疫苗、腦膜炎雙球菌疫苗和C型肝炎疫苗。建議每年接種流感疫苗，以預防季節性流感病毒，特別針對老年人、孕婦、醫護人員和患有慢性疾病的人等高風險族群。 Tdap 疫苗每 10 年接種一次加強針，以持續預防破傷風、白喉和百日咳。

建議65歲及以上成年人以及患有某些疾病的未滿18歲人群接種肺炎球菌疫苗，以預防肺炎球菌引起的肺炎、腦膜炎和血液感染疾病。建議50歲以上成年人接種帶狀皰疹疫苗，以預防帶狀皰疹（一種由水痘帶狀皰疹病毒引起的疼痛性皮疹）。建議26歲以下成年人人類乳突病毒(HPV)疫苗，以預防子宮頸癌、肛門癌、其他癌症以及生殖器濕疣。

治療和預防策略的進步，包括甲肝和B肝疫苗，對於控制丙肝病毒感染疾病和預防肝臟相關併發症至關重要。疫苗接種建議因年齡、健康狀況、職業、旅遊歷史和其他因素而異，因此諮詢您的醫療保健提供者或公共衛生部門，以確定適合每個人的疫苗接種時間表至關重要。

根據美國國家生物技術資訊中心 (NCBI) 的數據，美國和其他地區每年有許多成年人死於疫苗可預防的疾病。此外，美國疾病管制與預防中心 (CDC) 表示，流感疫苗對慢性病患者、老年人和孕婦至關重要，應每年接種。根據 CDC 的建議，成年人應接種一劑 Tdap（破傷風、白喉、百日咳）疫苗以預防百日咳。成年人每 10 年接種一次破傷風和白喉疫苗。此外，孕婦應在懷孕期間每 27 至 36 週接種一次 Tdap 疫苗。

政府加大對疾病預防的舉措是否會推動成人疫苗市場的成長？

隨著各國政府為預防某些疾病和流行病而採取的措施日益增多，全球成人疫苗市場可望大幅擴張。世界各國政府已經意識到疫苗接種對保護公眾健康，尤其是成年人健康的重要性。因此，各國正在實施各種計畫和舉措，以促進成年人接種疫苗，包括進行公眾意識提升宣傳活動，以及在醫療保健和旅遊等特定行業強制接種疫苗。

各國政府為預防某些疾病和流行病而做出的越來越多的努力預計將推動全球成人疫苗市場的發展。根據國家衛生使命，印度已設定了消除麻疹和德國德國麻疹的目標，因此於2017年透過分階段宣傳活動引入了麻疹-德國德國麻疹(MR)疫苗。 MR宣傳活動旨在為約410萬名9個月至15歲的兒童接種兩劑疫苗，分別在9至12個月和德國麻疹目前德國麻疹常規作為MR疫苗接種的一部分。

總體而言，未來幾年全球成人疫苗市場的成長預計將由政府主導的鼓勵成人接種疫苗的努力所推動。各國政府將疫苗接種作為公共衛生計畫的基石，希望最大限度地減輕疫苗可預防疾病的負擔，增強人口免疫力，並保障全球成年人的健康和福祉。

農村和偏遠地區缺乏意識將如何影響成人疫苗市場？

全球成人疫苗接種市場的擴張可能面臨巨大挑戰，因為人們對成人疫苗接種益處的了解有限，尤其是在開發中國家。這種認知的缺乏不僅影響新興經濟體，也影響到那些往往難以獲得醫療保健資訊和服務的偏遠農村地區。不了解成人疫苗接種必要性的人可能不會尋求或優先考慮建議的疫苗，從而限制了市場的成長。

此外，成人疫苗的前期成本可能會成為推廣的障礙，尤其是在醫療資金有限的地區。除了資金障礙外，物流問題也是阻礙全球成人疫苗市場成長的實施障礙。缺乏有效的提醒機制來鼓勵接種疫苗，導致人們錯失接種疫苗的機會。

透過提高意識、降低價格和簡化疫苗供應系統，可以增強全球成人疫苗產業的發展潛力，相關人員可以培養和提升擴大全球成人預防性醫療保健覆蓋率的潛力。

目錄

第1章全球成人疫苗市場簡介

  • 市場概覽
  • 研究範圍
  • 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

第4章全球成人疫苗市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

5. 全球成人疫苗市場（按疫苗）

  • 概述
  • 肝炎
  • 人類乳突病毒
  • 流感
  • 帶狀皰疹
  • 其他

6. 全球成人疫苗市場（依疫苗類型）

  • 概述
  • 單價疫苗
  • 多效價疫苗

7. 全球成人疫苗市場（依技術）

  • 概述
  • 活病毒疫苗
  • 去活化病毒/細菌疫苗
  • 類毒素疫苗
  • 重組疫苗
  • 聯合疫苗

8. 全球成人疫苗市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中東和非洲
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非
    • 其他中東和非洲地區

9. 全球成人疫苗市場競爭格局

  • 概述
  • 各公司市場排名
  • 重點發展策略

第10章 公司簡介

  • Pfizer, Inc.
  • GlaxoSmithKline Plc.
  • Sanofi Pasteur
  • Merck & Co.
  • CSL Limited
  • Johnson & Johnson
  • Medimmune
  • Serum Institute of India
  • AstraZeneca Plc
  • Novartis

第11章 附錄

相關調查

簡介目錄
Product Code: 37358

Adult Vaccine Market Valuation - 2026-2032

The rising prevalence of infectious diseases such as influenza, hepatitis, and zoster, as well as government programs to raise awareness of the importance of immunization are driving expansion in the adult vaccine market. The global adult vaccine market study offers a comprehensive assessment of the market. The market size surpass USD 17279.87 Million valued in 2024 to reach a valuation of around USD 27750.04 Million by 2032.

In addition to this, the rising increased research into vaccination technologies and growing government funding are enabling the market to grow at a CAGR of 6.10% from 2026 to 2032.

Adult Vaccine Market: Definition/ Overview

Adult vaccines are immunizations designed for individuals aged 18 and older, aimed at preventing infectious diseases and reducing the risk of severe illness, complications, and pathogen transmission. These vaccines can be administered as primary or booster doses to maintain immunity from childhood vaccines.

Some common types of adult vaccines include influenza (Flu), tetanus, diphtheria, and pertussis (Tdap), pneumonia, shingles, human papillomavirus (HPV), hepatitis A and B, measles, mumps, and rubella (MMR), chickenpox, meningococcal, and hepatitis C. Influenza vaccines are recommended annually to protect against seasonal influenza viruses, especially for high-risk groups like older adults, pregnant women, healthcare workers, and individuals with chronic health conditions. Tdap vaccines are given as a booster every 10 years to maintain protection against tetanus, diphtheria, and pertussis.

Pneumococcal vaccines are recommended for adults 65 years and older, as well as younger adults with certain medical conditions, to prevent pneumonia, meningitis, and bloodstream infections caused by Streptococcus pneumoniae bacteria. Herpes zoster vaccines are recommended for adults 50 years and older to prevent shingles, a painful rash caused by the varicella-zoster virus. HPV vaccines are recommended for adults up to age 26 to protect against cervical, anal, and other cancers, as well as genital warts.

Advancements in treatment and prevention strategies, including vaccines for hepatitis A and B, are essential in managing HCV infections and preventing liver-related complications. Vaccination recommendations may vary based on age, health status, occupation, travel history, and other factors, so consulting with healthcare providers or public health authorities is crucial for determining the appropriate vaccine schedule for each individual.

According to the NCBI, vaccine-preventable diseases kill many adults each year in countries such as the United States. Furthermore, according to the Center for Disease Control (CDC), individuals require an influenza vaccine each year since the vaccine is crucial for those with chronic illnesses, the elderly and pregnant women. According to CDC recommendations each adult must be immunized once with the Tdap (Tetanus, Diphtheria, and Pertussis) vaccine to protect against whooping cough if they have not already been immunized. Adults are also given a booster immunization against tetanus and diphtheria every 10 years. Additionally, pregnant women should get immunized with the Tdap vaccination every 27 to 36 weeks of pregnancy.

Will Rise in Government Initiatives Focusing on Prevention of Diseases Drive the Growth of the Adult Vaccines Market?

The global adult vaccinations market is on track for significant development, driven by an increasing number of government efforts aimed at preventing certain diseases and epidemics. Governments around the world are recognizing the importance of vaccination in protecting public health, particularly among adults. As a result countries are implementing a variety of programs and policies to promote adult vaccination, ranging from public awareness campaigns to vaccine mandates in certain industries such as healthcare and tourism.

The growing number of government attempts to avoid specific diseases and epidemics is predicted to drive the worldwide adult vaccines market. According to the National Health Mission, India is committed to the aim of eliminating measles and controlling rubella, hence the Measles Rubella (MR) vaccine was introduced in the country through a phased campaign in 2017. The Measles-Rubella (MR) campaign aims to immunize around 4.1 million children aged 9 months to 15 years with two doses administered at 9-12 months and 16-24 months. The rubella component is now routinely administered as part of the MR vaccination.

Overall, the growth of the global adult vaccines market in the coming years and government-coordinated efforts to encourage adult immunization are projected to drive. By prioritizing vaccination as a cornerstone of public health policy, governments hope to minimize the burden of vaccine-preventable diseases, boost population immunity and protect the health and well-being of adults worldwide.

How will Lack of Awareness among the Rural Areas or Remote Areas Impact Adult Vaccine Market?

The expansion of the global adult vaccination sector may encounter considerable challenges due to a limited understanding of the benefits of adult vaccination particularly in developing countries. This lack of awareness affects not only emerging nations but also isolated and rural communities where access to healthcare information and services is frequently limited. Individuals who do not understand the necessity of adult vaccination may not seek out or prioritize receiving recommended vaccines limiting market growth.

Furthermore, the initial expenses associated with adult immunizations can be a barrier to expansion, especially in places where healthcare funds are limited. In addition to financial hurdles, logistical issues create implementation barriers that hamper the growth of the worldwide adult vaccines sector. The lack of effective reminder mechanisms to encourage people to be vaccinated can lead to missed opportunities for immunization.

The global adult vaccines industry's development potential by raising awareness, lowering prices, and streamlining vaccine delivery systems, stakeholders can help promote and develop the potential to enable greater access to preventive healthcare for adults globally.

Category-Wise Acumens

How the Adult Vaccine Market is divided into Categories based on Specific Disease of Vaccine Targets?

The worldwide adult vaccinations market is divided according to the specific disease that the vaccine addresses. These include varicella (chickenpox), influenza, human papillomavirus (HPV), tetanus, measles, shingles, pneumococcal illness, and others.

Among them, the influenza vaccine category is currently leading, accounting for over 55% of the global market share in 2022. This dominance is projected to continue, with estimates showing the fastest growth rate for this segment in the future years. The broad prevalence of seasonal flu, an acute respiratory illness caused by the influenza virus is a major driver of the demand for adult vaccine .

According to the World Health Organization (WHO), seasonal flu causes over 400,000 fatalities each year, largely owing to respiratory problems. Furthermore, WHO data show that influenza is especially hazardous for persons over 60 in developed countries, underscoring the importance of broad immunization in this age range.

How the Incising Prevalence of Bacterial and Viral Infection will Drive the Multivalent Vaccines Segments?

The global adult vaccinations industry is divided into two sectors based on the type of vaccine used monovalent and multivalent. Particularly, in 2022, the multivalent vaccines segment contributed significantly to the global market share. According to projections, this segment's influence in the market will grow even stronger in the next years. This expected growth over the evaluation period can be linked to a significant increase in bacterial and viral infections found in Asian and Latin American countries, among others, around the world.

The division of the adult vaccinations market into monovalent and multivalent categories highlights the wide range of vaccines available to treat numerous infectious diseases in adults. In recent years, the multivalent vaccines category has emerged as a key driver of industry growth, thanks to its capacity to defend against several infections with a single vaccination formulation. This immunization efficiency is especially beneficial in areas with increased rates of both bacterial and viral illnesses.

Overall, the trajectory of the multivalent vaccines segment's growth in the worldwide adult vaccines business emphasizes the necessity of innovation and adaptation in dealing with changing healthcare concerns. Multivalent vaccinations, which provide broad-spectrum protection against many pathogens, have the potential to play a critical role in advancing public health goals and lowering the global burden of infectious illnesses.

Country/Region-wise Acumens

How does the North America Account for Major Share in Adult Vaccine Market over the Analysis?

The North American region, which commanded a significant 60% share of the worldwide adult vaccines market in 2022, is expected to maintain its dominance in terms of market revenue share between 2023 and 2030. This expected ongoing leadership in the global market can be linked to an increase in the frequency of viral infections among adults particularly in Canada and the United States.

The North American market is predicted to rise significantly due to an increase in viral infections among adults underscoring the importance of vaccination in disease prevention and public health risk reduction. Particularly, the National Institutes of Health (NIH) found that the influenza vaccine alone reduces approximately 90,000 hospitalizations among older persons in the United States each year, emphasizing the relevance of immunization in reducing healthcare expenses.

The US Centers for Disease Control and Prevention (CDC) has published recommendations for adults to get vaccinated against numerous diseases on a regular basis. Tetanus, diphtheria, and pertussis (Tdap) vaccinations, as well as seasonal influenza, are recommended for all adults. The CDC also advises herpes zoster vaccine for people over the age of 50 and pneumococcal vaccination for adults 65 and older.

How Does the European Market Experience Significant Growth in Adult Vaccine Market?

The European adult vaccine industry is predicted to develop significantly, driven by broad immunization recommendations from EU member states. Notably, as of January 2022, roughly 29 out of 30 EU nations had approved influenza vaccination, demonstrating a strong commitment to preventive healthcare measures. Furthermore, 21 EU nations suggest immunization for pneumonia, demonstrating the importance of protecting adults against respiratory illnesses.

These comprehensive vaccination guidelines from EU countries represent a concerted effort to promote adult immunization and prevent vaccine-preventable diseases. By campaigning for immunization against a variety of infectious agents, European countries are taking proactive actions to protect public health and minimize the burden of preventable illnesses in adults.

As EU countries emphasize immunization efforts and increase access to adult vaccines, the region is positioned to become a leading market for adult vaccination, benefiting both individuals and healthcare systems.

Competitive Landscape

The adult vaccine market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the adult vaccine market include:

  • Solvay Pharmaceuticals
  • Moderna
  • BioCSL (Seqirus)
  • Aventis Pasteur
  • Sanofi Pasteur
  • Pfizer Inc.
  • Merck & Co. Inc.
  • GlaxoSmithKline Plc
  • Novartis AG
  • Johnson & Johnson
  • BioNTech
  • Bharat Biotech International Limited
  • Zhifei
  • Wyeth Vaccines
  • AstraZeneca Plc
  • Medimmune
  • Sinovac
  • Baxter International Healthcare Company
  • Chiron Vaccines
  • Serum Institute of India

Latest Developments

  • In August 2022, the WHO Strategic Advisory Group of Experts on Immunization (SAGE) released interim recommendations for the use of the Pfizer BioNTech (BNT162b2) vaccine against COVID-19. This post summarizes those interim suggestions; you can find the complete advice document here. According to SAGE, the Pfizer-BioNTech COVID-19 mRNA vaccine is both safe and efficacious.
  • In August 2020, Novavax and Serum Institute of India inked a license agreement for the manufacturing and sale of their innovative COVID-19 vaccine candidate, NVX-CoV2373, in low- and middle-income countries, including India. This would improve the company's revenue.

Adult Vaccine Market, By Category

  • Vaccine:
  • Varicella
  • Influenza
  • Human Papillomavirus
  • Tetanus
  • Measles
  • Zoster
  • Pneumococcal
  • Vaccine Type:
  • Monovalent Vaccines
  • Multivalent Vaccines
  • Technology:
  • Live Attenuated Vaccines
  • Inactivated Viral/Bacterial Vaccines
  • Toxoid Vaccines
  • Recombinant Vaccines
  • Conjugate Vaccines
  • End-User:
  • Private Healthcare Firms
  • Government Hospitals
  • Region:
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL ADULT VACCINE MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL ADULT VACCINE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porter's Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL ADULT VACCINE MARKET, BY VACCINE

  • 5.1 Overview
  • 5.2 Hepatitis
  • 5.3 Human Papillomavirus
  • 5.4 Influenza
  • 5.5 Zoster
  • 5.6 Others

6 GLOBAL ADULT VACCINE MARKET, BY VACCINE-TYPE

  • 6.1 Overview
  • 6.2 Monovalent vaccines
  • 6.3 Multivalent vaccines

7 GLOBAL ADULT VACCINE MARKET, BY TECHNOLOGY

  • 7.1 Overview
  • 7.2 Live Attenuated Vaccines
  • 7.3 Inactivated Viral/Bacterial Vaccines
  • 7.4 Toxoid Vaccines
  • 7.5 Recombinant Vaccines
  • 7.6 Conjugate Vaccines

8 GLOBAL ADULT VACCINE MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 The U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 The U.K.
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Argentina
    • 8.5.3 Rest of LATAM
  • 8.6 Middle East and Africa
    • 8.6.1 UAE
    • 8.6.2 Saudi Arabia
    • 8.6.3 South Africa
    • 8.6.4 Rest of the Middle East and Africa

9 GLOBAL ADULT VACCINE MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Pfizer, Inc.
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 GlaxoSmithKline Plc.
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Sanofi Pasteur
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Merck & Co.
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 CSL Limited
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Johnson & Johnson
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Medimmune
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Serum Institute of India
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 AstraZeneca Plc
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Novartis
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments

11 Appendix

Related Research